| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-4241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_686d41adab18f72546d470c8ecbd00dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af226973a2cded1df8049b2cdb9fa5d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bc66fec4880493d43d73e88d4974da1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a8cf1c6ac5dd6859f36b670a150f509 |
| publicationDate |
2017-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-107108746-A |
| titleOfInvention |
Antibodies capable of neutralizing substances having an activity of replacing the function of coagulation factor VIII (FVIII) |
| abstract |
The inventors of the present invention attempted to prepare an antibody that neutralizes the activity of a substance having an activity functionally replacing FVIII for use in a method of measuring reactivity of FVIII in the presence of a substance having an activity functionally replacing FVIII. As a result, the inventors found that by using the prepared antibodies, FVIII activity in plasma of hemophilia A patients could be accurately assessed by an APTT-based one-step coagulation assay, and also found that carrying FVIII could be accurately assessed by an APTT-based Bethesda assay FVIII inhibitor titers in plasma of hemophilia A patients with inhibitors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107449925-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106716139-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11150254-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112513096-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112513096-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214623-B2 |
| priorityDate |
2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |